Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 8/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PHGDH | O43175 | 1/20 | 0.39 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5496957 | 0.89 | CRHR1 (0.43) | CRHR1CYP1A2CYP2C19TP53MAPT | |
| SCHEMBL27624988 | 0.83 | CRHR1 (0.52) | CRHR1CYP1A2CYP2C19TP53MAPT | |
| SCHEMBL4763636 | 0.82 | CRHR1 (0.56) | CRHR1CYP1A2CYP2C19PHGDHSRD5A1 | |
| SCHEMBL5100161 | 0.79 | CRHR1 (0.47) | CRHR1TP53MAPTSMN1; SMN2PHGDH | |
| SCHEMBL4770391 | 0.79 | CRHR1 (0.53) | CRHR1CYP1A2CYP2C19PHGDHP2RX7 | |
| SCHEMBL6746234 | 0.78 | CRHR1 (0.57) | CRHR1CYP1A2CYP2C19PHGDHTRPV1 | |
| SCHEMBL4762012 | 0.78 | CRHR1 (0.52) | CRHR1CYP1A2CYP2C19TRPV1SRD5A1 | |
| SCHEMBL27624999 | 0.77 | CRHR1 (0.49) | CRHR1CYP1A2CYP2C19PHGDHTRPV1 | |
| SCHEMBL5487813 | 0.77 | CRHR1 (0.50) | CRHR1 | |
| SCHEMBL4945689 | 0.76 | CRHR1 (0.55) | CRHR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172255-A1 | Condensed N-Heterocyclic Compounds and their Use as CRF Receptor Antagonists | SB PHARMCO PUERTO RICO INC | 2011-07-14 | — | — | US | disclosed |
| EP-2186813-A1 | Condensed N-heterocyclic compounds and their use as CRF receptor antagonists | SmithKline Beecham (Cork) Limited (IE) | 2010-05-19 | — | — | EP | disclosed |
| US-7462622-B2 | Pyrrolo[2, 3-d] pyrimidine derivatives as corticotropin releasing factor antagonists | GLAXO GROUP LIMITED (GB) | 2008-12-09 | — | — | US | disclosed |
| US-7427630-B2 | Condensed N-heterocyclic compounds and their use as CRF receptor antagonists | SB PHARMACO PUERTO RICO INC. (US) | 2008-09-23 | — | — | US | disclosed |
| EP-1395591-B1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-06-04 | — | — | EP | disclosed |
| EP-1383747-B1 | FUSED PYRIMIDINES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR (CRF) | GLAXO GROUP LTD (GB) | 2008-02-20 | — | — | EP | disclosed |
| US-7279474-B2 | Substituted pyrrolo[2,3-d]pyrimidines as antagonists of the corticotropin releasing factor (CRF) | GLAXO GROUP LIMITED (GB) | 2007-10-09 | — | — | US | disclosed |
| US-20070004708-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | NEUROCRINE BIOSCIENCES, INC. | 2007-01-04 | — | — | US | disclosed |
| CN-1649848-A | Fused pyrimidines derivatives as antagonists of the corticotropin releasing factor (CRF) | GLAXO GROUP LTD (GB) | 2005-08-03 | — | — | CN | disclosed |
| US-20050054661-A1 | Corticotropin releasing factor antagonists | GLAXO GROUP LIMITED (GB) | 2005-03-10 | — | — | US | disclosed |
| US-20040176400-A1 | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) | GLAXO GROUP LIMITED (GB) | 2004-09-09 | — | — | US | disclosed |
| CN-1512883-A | CRF receptor antagonists | — | 2004-07-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172255-A1 | Condensed N-Heterocyclic Compounds and their Use as CRF Receptor Antagonists | CRH, CRHR1, CRHR2 | CRHR1 2/4885CYP1A2 1490/4885CYP2C19 602/4885 |
| US-20050054661-A1 | Corticotropin releasing factor antagonists | CRHR1, CRH, CRHR2 | CRHR1 1/4885CYP1A2 1220/4885CYP2C19 751/4885 |
| US-20070004708-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | CRHR2, NR3C2, CRHR1 | CRHR1 3/4885CYP1A2 454/4885CYP2C19 453/4885 |
| US-20040176400-A1 | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) | CRH, CRHR1, CRHR2 | CRHR1 2/4885CYP1A2 1826/4885CYP2C19 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.